Dilemma of Reporting Incidental Findings in Newborn Screening Programs for SCID: Parents’ Perspective on Ataxia Telangiectasia
Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an e...
Saved in:
Published in | Frontiers in immunology Vol. 10; p. 2438 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
06.11.2019
|
Subjects | |
Online Access | Get full text |
ISSN | 1664-3224 1664-3224 |
DOI | 10.3389/fimmu.2019.02438 |
Cover
Abstract | Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T.
A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population.
A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic "golden years" with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available.
Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders. |
---|---|
AbstractList | Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T.Methods: A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population.Results: A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic “golden years” with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available.Conclusions: Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders. Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T. Methods: A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population. Results: A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic "golden years" with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available. Conclusions: Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders.Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T. Methods: A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population. Results: A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic "golden years" with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available. Conclusions: Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders. Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T. Methods: A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population. Results: A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic “golden years” with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available. Conclusions: Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders. Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T. A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population. A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic "golden years" with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available. Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders. |
Author | de Vries, Martine C. Weemaes, Corry M. R. Henneman, Lidewij Willemsen, Michèl A. A. P. van der Burg, Mirjam Hulst, Myrthe Blom, Maartje Schoenaker, Michiel H. D. |
AuthorAffiliation | 2 Department of Pediatric Neurology, Radboudumc Amalia Children's Hospital and Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center , Nijmegen , Netherlands 4 Department of Medical Ethics and Health Law, Leiden University Medical Center , Leiden , Netherlands 1 Department of Pediatrics, Leiden University Medical Centre , Leiden , Netherlands 6 Department of Clinical Genetics, Amsterdam Reproduction & Development Research Institute, Vrije Universiteit Amsterdam, Amsterdam UMC , Amsterdam , Netherlands 5 Department of Pediatrics, Radboudumc Amalia Children's Hospital, Radboud University Medical Center , Nijmegen , Netherlands 3 Department of Biologicals, Innovation and Screening, National Institute for Public Health and the Environment , Bilthoven , Netherlands |
AuthorAffiliation_xml | – name: 1 Department of Pediatrics, Leiden University Medical Centre , Leiden , Netherlands – name: 3 Department of Biologicals, Innovation and Screening, National Institute for Public Health and the Environment , Bilthoven , Netherlands – name: 4 Department of Medical Ethics and Health Law, Leiden University Medical Center , Leiden , Netherlands – name: 6 Department of Clinical Genetics, Amsterdam Reproduction & Development Research Institute, Vrije Universiteit Amsterdam, Amsterdam UMC , Amsterdam , Netherlands – name: 5 Department of Pediatrics, Radboudumc Amalia Children's Hospital, Radboud University Medical Center , Nijmegen , Netherlands – name: 2 Department of Pediatric Neurology, Radboudumc Amalia Children's Hospital and Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center , Nijmegen , Netherlands |
Author_xml | – sequence: 1 givenname: Maartje surname: Blom fullname: Blom, Maartje – sequence: 2 givenname: Michiel H. D. surname: Schoenaker fullname: Schoenaker, Michiel H. D. – sequence: 3 givenname: Myrthe surname: Hulst fullname: Hulst, Myrthe – sequence: 4 givenname: Martine C. surname: de Vries fullname: de Vries, Martine C. – sequence: 5 givenname: Corry M. R. surname: Weemaes fullname: Weemaes, Corry M. R. – sequence: 6 givenname: Michèl A. A. P. surname: Willemsen fullname: Willemsen, Michèl A. A. P. – sequence: 7 givenname: Lidewij surname: Henneman fullname: Henneman, Lidewij – sequence: 8 givenname: Mirjam surname: van der Burg fullname: van der Burg, Mirjam |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31781088$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1uEzEUhUeoiP7QPSvkJZsE_43HwwKpSilEqiCiZW3d8dwJrmbsYE9auutr8Ho8CU7SohYJb2xdn_NdXfscFns-eCyKV4xOhdD1284Nw3rKKaunlEuhnxUHTCk5EZzLvUfn_eI4pSual6yFEOWLYl-wSjOq9UFxd-p6HAYgoSNfcRXi6PySzL11LfoRenLmfJtLiThPPuNNE6InFzYi-o1wEcMywpBIFyK5mM1P35EFxOxMv-9-kQXGtEI7umskwZOTEX46IJfYg1-6XIfk4GXxvIM-4fH9flR8O_twOfs0Of_ycT47OZ9Yqfg4KTXUeVTkqFTeNJSqY2glb1hd6Q4AeN02NYIsK1BNrTpNq7JkteKqEp0WR8V8x20DXJlVdAPEWxPAmW0hxKWBPLzt0aAEDgoVNJWUrZK1LktBW-RtaS2WmFnvd6zVuhmwtXneCP0T6NMb776bZbg2SpeMsioD3twDYvixxjSawSWLfX4YDOtkuOBUVFpLlaWvH_f62-ThC7NA7QQ2hpQidsa6EUYXNq1dbxg1m7iYbVzMJi5mG5dspP8YH9j_tfwBJ0LGDg |
CitedBy_id | crossref_primary_10_1007_s12687_020_00488_y crossref_primary_10_1016_j_jaci_2020_12_633 crossref_primary_10_1093_bmb_ldaa017 crossref_primary_10_3390_ijns8030040 crossref_primary_10_1111_dme_15131 crossref_primary_10_3389_fped_2021_706394 crossref_primary_10_3390_ijns9030051 crossref_primary_10_1007_s10875_020_00886_4 crossref_primary_10_1080_08820139_2020_1723104 crossref_primary_10_3390_genes11091018 crossref_primary_10_3389_fimmu_2021_686333 crossref_primary_10_1007_s12026_021_09216_1 crossref_primary_10_1080_14636778_2022_2091533 crossref_primary_10_1038_s41431_023_01469_8 crossref_primary_10_3390_ijns10020038 crossref_primary_10_1080_1744666X_2020_1810570 crossref_primary_10_1007_s11882_020_00955_z crossref_primary_10_1097_MOP_0000000000001291 crossref_primary_10_3390_ijns9020022 |
Cites_doi | 10.1016/j.jaci.2004.10.012 10.1111/cge.12710 10.1182/blood-2011-08-371021 10.1016/j.clim.2019.03.012 10.1093/jnci/djy028 10.1186/1750-1172-7-15 10.1016/j.srhc.2018.06.001 10.1007/s00431-019-03479-5 10.1002/mus.24100 10.1001/jama.2014.9132 10.1186/1471-2288-6-5 10.1007/s10875-016-0347-5 10.1111/dmcn.13424 10.1007/s10875-012-9846-1 10.1542/peds.2018-2300 10.1111/imr.12729 10.3389/fimmu.2017.01448 10.1186/s13023-016-0543-7 10.3390/ijns3020015 10.1159/000314644 10.1097/DBP.0b013e3181eedf01 10.1111/hex.12047 10.1111/j.1753-6405.2012.00854.x 10.1002/mgg3.353 |
ContentType | Journal Article |
Copyright | Copyright © 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg. Copyright © 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg. 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg |
Copyright_xml | – notice: Copyright © 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg. – notice: Copyright © 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg. 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3389/fimmu.2019.02438 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ - The Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
ExternalDocumentID | oai_doaj_org_article_e4a2a6e6ab744d64985530de2d5cce5e PMC6851017 31781088 10_3389_fimmu_2019_02438 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c462t-58a9201e2e6601e8a56f1ec42b1978faaa29db9ea457a6b96f807551962673f83 |
IEDL.DBID | M48 |
ISSN | 1664-3224 |
IngestDate | Wed Aug 27 01:19:06 EDT 2025 Thu Aug 21 18:22:54 EDT 2025 Fri Sep 05 11:07:41 EDT 2025 Thu Jan 02 22:58:50 EST 2025 Thu Apr 24 23:02:38 EDT 2025 Tue Jul 01 00:39:50 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | questionnaire incidental finding A-T ataxia telangiectasia parents' perspective severe combined immunodeficiency SCID newborn screening |
Language | English |
License | Copyright © 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c462t-58a9201e2e6601e8a56f1ec42b1978faaa29db9ea457a6b96f807551962673f83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Jolan Eszter Walter, University of South Florida, United States This article was submitted to Primary Immunodeficiencies, a section of the journal Frontiers in Immunology Reviewed by: Anders Fasth, University of Gothenburg, Sweden; Nizar Mahlaoui, Necker-Enfants Malades Hospital, France |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2019.02438 |
PMID | 31781088 |
PQID | 2320378846 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_e4a2a6e6ab744d64985530de2d5cce5e pubmedcentral_primary_oai_pubmedcentral_nih_gov_6851017 proquest_miscellaneous_2320378846 pubmed_primary_31781088 crossref_citationtrail_10_3389_fimmu_2019_02438 crossref_primary_10_3389_fimmu_2019_02438 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-11-06 |
PublicationDateYYYYMMDD | 2019-11-06 |
PublicationDate_xml | – month: 11 year: 2019 text: 2019-11-06 day: 06 |
PublicationDecade | 2010 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in immunology |
PublicationTitleAlternate | Front Immunol |
PublicationYear | 2019 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | B20 B21 (B15) 2015 Amatuni (B3) 2019; 143 Wood (B24) 2014; 49 Chan (B4) 2005; 115 Dorsey (B7) 2017; 3 Boardman (B25) 2018; 6 Mallott (B13) 2013; 33 Puck (B8) 2019; 287 van Os (B10) 2017; 59 Weigelt (B12) 2018; 110 Schoenaker (B17) 2019 Borte (B14) 2012; 119 (B26) 2019 Kwan (B1) 2014; 312 Levy (B23) 2010; 31 B18 B19 van Os (B11) 2016; 90 Rechavi (B2) 2017; 8 Barbaro (B5) 2017; 37 Nakash (B30) 2006; 6 Weinreich (B16) 2012; 7 Morton (B29) 2012; 36 Hasegawa (B27) 2011; 14 Thomas (B6) 2019; 202 Wiklund (B22) 2018; 17 Hayeems (B28) 2015; 18 Rothblum-Oviatt (B9) 2016; 11 |
References_xml | – volume: 115 start-page: 391 year: 2005 ident: B4 article-title: Development of population-based newborn screening for severe combined immunodeficiency publication-title: J Allergy Clin Immunol. doi: 10.1016/j.jaci.2004.10.012 – volume: 90 start-page: 105 year: 2016 ident: B11 article-title: Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline publication-title: Clin Genet. doi: 10.1111/cge.12710 – volume: 119 start-page: 2552 year: 2012 ident: B14 article-title: Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR publication-title: Blood. doi: 10.1182/blood-2011-08-371021 – ident: B20 – volume-title: Neonatal Screening for Spinal Muscular Atrophy. year: 2019 ident: B26 – volume: 202 start-page: 33 year: 2019 ident: B6 article-title: Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results publication-title: Clin Immunol. doi: 10.1016/j.clim.2019.03.012 – volume: 110 start-page: 1030 year: 2018 ident: B12 article-title: The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers publication-title: J Natl Cancer Inst. doi: 10.1093/jnci/djy028 – ident: B21 – volume: 7 start-page: 15 year: 2012 ident: B16 article-title: Public support for neonatal screening for Pompe disease, a broad-phenotype condition publication-title: Orphanet J Rare Dis. doi: 10.1186/1750-1172-7-15 – ident: B18 – volume: 17 start-page: 35 year: 2018 ident: B22 article-title: New parents' experience of information and sense of security related to postnatal care: a systematic review publication-title: Sex Reprod Healthc. doi: 10.1016/j.srhc.2018.06.001 – year: 2019 ident: B17 article-title: Early diagnosis of Ataxia Telangiectasia in the neonatal phase: a parents' perspective doi: 10.1007/s00431-019-03479-5 – volume: 49 start-page: 822 year: 2014 ident: B24 article-title: Parental attitudes toward newborn screening for Duchenne/Becker muscular dystrophy and spinal muscular atrophy publication-title: Muscle Nerve. doi: 10.1002/mus.24100 – volume: 312 start-page: 729 year: 2014 ident: B1 article-title: Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States publication-title: JAMA. doi: 10.1001/jama.2014.9132 – volume: 6 start-page: 5 year: 2006 ident: B30 article-title: Maximising response to postal questionnaires–a systematic review of randomised trials in health research publication-title: BMC Med Res Methodol. doi: 10.1186/1471-2288-6-5 – volume: 37 start-page: 51 year: 2017 ident: B5 article-title: Newborn screening for severe primary immunodeficiency diseases in sweden-a 2-year pilot TREC and KREC screening study publication-title: J Clin Immunol. doi: 10.1007/s10875-016-0347-5 – volume-title: Neonatal Screening: New Recommendations. year: 2015 ident: B15 – volume: 59 start-page: 680 year: 2017 ident: B10 article-title: Ataxia-telangiectasia: recommendations for multidisciplinary treatment publication-title: Dev Med Child Neurol. doi: 10.1111/dmcn.13424 – volume: 33 start-page: 540 year: 2013 ident: B13 article-title: Newborn screening for SCID identifies patients with ataxia telangiectasia publication-title: J Clin Immunol. doi: 10.1007/s10875-012-9846-1 – volume: 143 start-page: e20182300 year: 2019 ident: B3 article-title: Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California, 2010-2017 publication-title: Pediatrics. doi: 10.1542/peds.2018-2300 – volume: 287 start-page: 241 year: 2019 ident: B8 article-title: Newborn screening for severe combined immunodeficiency and T-cell lymphopenia publication-title: Immunol Rev. doi: 10.1111/imr.12729 – volume: 8 start-page: 1448 year: 2017 ident: B2 article-title: First year of Israeli newborn screening for severe combined immunodeficiency-clinical achievements and insights publication-title: Front Immunol. doi: 10.3389/fimmu.2017.01448 – volume: 11 start-page: 159 year: 2016 ident: B9 article-title: Ataxia telangiectasia: a review publication-title: Orphan J Rare Dis. doi: 10.1186/s13023-016-0543-7 – volume: 3 start-page: 15 year: 2017 ident: B7 article-title: Newborn screening for severe combined immunodeficiency in the US: current status and approach to management publication-title: Int J Neonatal Screen. doi: 10.3390/ijns3020015 – volume: 14 start-page: 298 year: 2011 ident: B27 article-title: Parental attitudes toward ethical and social issues surrounding the expansion of newborn screening using new technologies publication-title: Public Health Genomics. doi: 10.1159/000314644 – volume: 31 start-page: 622 year: 2010 ident: B23 article-title: An overview of newborn screening publication-title: J Dev Behav Pediatr. doi: 10.1097/DBP.0b013e3181eedf01 – volume: 18 start-page: 419 year: 2015 ident: B28 article-title: Expectations and values about expanded newborn screening: a public engagement study publication-title: Health Expect. doi: 10.1111/hex.12047 – volume: 36 start-page: 106 year: 2012 ident: B29 article-title: In the 21st Century, what is an acceptable response rate? publication-title: Aust N Z J Public Health. doi: 10.1111/j.1753-6405.2012.00854.x – ident: B19 – volume: 6 start-page: 99 year: 2018 ident: B25 article-title: Newborn genetic screening for spinal muscular atrophy in the UK: the views of the general population publication-title: Mol Genet Genomic Med. doi: 10.1002/mgg3.353 |
SSID | ssj0000493335 |
Score | 2.3396897 |
Snippet | Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable... Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable... Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 2438 |
SubjectTerms | A-T ataxia telangiectasia Immunology incidental finding newborn screening SCID severe combined immunodeficiency |
SummonAdditionalLinks | – databaseName: DOAJ - The Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQSkhcEMuzvGQkLhxCE9txbW7LLtWCBKq0u9LeLMcZiyCaIppKy23_Bn-PX8KM3S0tQnDhmjiKMw_7m3jmG8aem1IE2veLqGMsFOi2aETtiyhlbAUIA0C1w-8_6OMz9e68Pt9q9UU5YZkeOAtuDMoLr0H7ZqJUq5U11OimBdHWIUANtPqWttwKpj5l3CulrPO5JEZhdhy7-XxFqVz2JZHwmZ19KNH1_wlj_p4qubX3TG-xm2vQyA_yZPfZNehvs-u5jeS3O-zyCF17Pvd8EXkG1LgfcfR8ahiK4JpPu1S7suRdz3FVQ7X3_CRQxg0NnOUUrSVH_MpPDt8eveIzKhEblj8uv_PZr2pMvuj5weAvOs9PgX50dnidqjDvsrPpm9PD42LdWaEISouhqI23KAoQoDEgA-NrHSsISjQVRpXRey9s21jwqp543VgdibMYwR6GPxMZjbzH9vpFDw8YV7psEJII35Ze6UrbEGUog4wVaQz0iI2v5OzCmnacul98dhh-kGZc0owjzbikmRF7sXniS6bc-MvY16S6zTgiy04X0ITc2oTcv0xoxJ5dKd6hc9GJie9hsVo6hJslEe4r_Iz72RA2r0LgZSq08hGb7JjIzlx27_Tdx0TgrU1aCR_-j8k_YjdIHKk8Uj9me8PXFTxBnDQ0T5NL_ATVbxVD priority: 102 providerName: Directory of Open Access Journals |
Title | Dilemma of Reporting Incidental Findings in Newborn Screening Programs for SCID: Parents’ Perspective on Ataxia Telangiectasia |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31781088 https://www.proquest.com/docview/2320378846 https://pubmed.ncbi.nlm.nih.gov/PMC6851017 https://doaj.org/article/e4a2a6e6ab744d64985530de2d5cce5e |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgCIkXxPfK2GQkJMRDtsRxXAdpmsZGGUigSlulvkWOc4agNWFNKm0v_O27c7KOogrxkofESWzfne939n0w9kaHwpLeD5xyLpCgiiAXiQlcHLtCgNAAFDv89Zs6mcgv02R6Gx7dT2Cz1rSjelKT-fnu5cXVAQr8PlmcqG_3XDmbLchLK92l_Hr6LrvnT4vIka8H-z87LBzHvuJmpJQMkJNld2659iMresqn81-HQf92pfxDN40esYc9qOSHHRc8ZnegesLud2Umr56y38co-rOZ4bXjHeBGfcVxZaCCojhuPip9bEvDy4rjqodsUfFTSx451HDcuXA1HPEtPz36fPyejymErG3e8vFtrCavK37YmsvS8DOgbdAS71OM5jM2GX08OzoJ-roLgZVKtEGiTYoTAQIUmmugTaJcBFaKPEKb0xljRFrkKRiZDI3KU-UoozFCQTSOhrHT8XO2UdUVbDIuVZgjYBGmCI1UkUqti21oYxeZfIicMWB7N7Oc2T4pOdXGOM_QOCG6ZJ4uGdEl83QZsHfLN351CTn-0fYDEW7ZjlJp-xv1_HvWS2YG0gijQFGHZKFkqqmSUgGiSKyFBAbs9Q3ZMxQ9Ok8xFdSLJkMwGlI6fonDeNGxwfJXCMt0hDIwYMMVBlnpy-qTqvzh03sr7dfJl__x3y32gEbrYyPVK7bRzhewjSCpzXf85gJeP02jHS8H14EaE4Q |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dilemma+of+Reporting+Incidental+Findings+in+Newborn+Screening+Programs+for+SCID%3A+Parents%27+Perspective+on+Ataxia+Telangiectasia&rft.jtitle=Frontiers+in+immunology&rft.au=Blom%2C+Maartje&rft.au=Schoenaker%2C+Michiel+H+D&rft.au=Hulst%2C+Myrthe&rft.au=de+Vries%2C+Martine+C&rft.date=2019-11-06&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=10&rft.spage=2438&rft_id=info:doi/10.3389%2Ffimmu.2019.02438&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |